期刊文献+

疟疾疫苗研究的现状和展望 被引量:12

Malaria vaccine: current status and perspective
下载PDF
导出
摘要 疟原虫抗药性及疟蚊对杀虫剂抗性的产生和迅速扩散迫切需要研究新的疟疾防治方法 ,以控制该传染病的流行。根据自愿者试验、动物模型及现场研究结果 ,研制疫苗预防疟疾是可行的。当前 ,全球科学家正在研制 3种类型的疟疾疫苗——抗红内期原虫疫苗、抗红前期原虫疫苗和传播阻断疫苗 ,其中一些候选疫苗已进入临床试验 ,并产生有意义的结果。由于疟原虫具有复杂的生活史、抗原变异和多种入侵途径 ,有效疫苗的研制将面临极大的困难 。 The emergency and rapid spread of drug resistant parasites and mosquitoes resistant to insecticides urgently demand new tools to control the disease. It is feasible to develop malaria vaccine based on animal and volunteers test. Scientists around the world are working on 3 types of malaria vaccine——pre erythrocytic, blood stage and transmission blocking. Some of the vaccine candidates are being tested in clinical trials and have been shown to be promising. It is very difficult to find a successful malaria vaccine due to its complex life cycle, antigen variations and multiple invasion pathways, but the vaccine will finally be developed.
作者 潘卫庆
出处 《第二军医大学学报》 CAS CSCD 北大核心 2004年第1期1-4,共4页 Academic Journal of Second Military Medical University
基金 世界卫生组织专项基金 ( IDA 2 0 198) 国家杰出青年科学基金 ( 3 0 2 2 5 0 41)
关键词 疟疾 疫苗 预防 红内期 红前期 疟原虫 malaria vaccine pre erythrocytic blood stage transmission blocking
  • 相关文献

参考文献12

  • 1[1]Hoffman SL,Goh LM,Luke TC,et al.Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites[J].J Infect Dis,2002,185(8):1155-1164.
  • 2[2]Wang R,Charoenvit Y,Corradin G,et al.Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine[J].J Immunol,1995,154(6):2784-2793.
  • 3[3]Roggero MA,Meraldi V,Lopez JA,et al.The synthetic,oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response[J].Eur J Immunol,2000,30(9):2679-2685.
  • 4[4]Tewari R,Spaccapelo R,Bistoni F,et al.Function of region Ⅰ and Ⅱ adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity[J].J Biol Chem,2002,277(49):47613-47618.
  • 5[5]Gordon DM,McGovern TW,Krzych U,et al.Safety,immunogenicity,and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B antigen subunit vaccine[J].J Infect Dis,1995,171(6):1576-1585.
  • 6[6]Stoute JA,Slaoui M,Heppner DG,et al.A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria[J].N Engl J Med,1997,336(2):86-91.
  • 7[7]Roggero MA,Weilenmann C,Bonelo A,et al.Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase Ⅰ clinical studies[J].Parassitologia,1999,41(1-3):421-424.
  • 8[8]Moorthy VS,Pinder M,Reece WH,et al.Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults[J].J Infect Dis,2003,188(8):1239-1244.
  • 9[9]Angov E,Aufiero BM,Turgeon AM,et al.Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine[J].Mol Biochem Parasitol,2003,128(2):195-204.
  • 10[10]Crewther PE,Matthew ML,Flegg RH,et al,Protective immune responses to apical membrane antigen1 of Plasmodium chabaudi involve recognition of strain-specific epitopes[J].Infect Immun,1996,64(8):3310-3317.

同被引文献163

引证文献12

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部